ILC is a luminal breast cancer that mostly expresses oestrogen receptor (ER) and responds well to treatments targeting ER function. However, if these endocrine interventions cease to be successful, it is notoriously difficult to treat disseminated ILC.
In contrast to most breast cancers, it is clear that ILC development, progression and phenotypical presentation is a direct consequence of functional cell-cell adhesion loss though E-cadherin inactivation. It is this event that enables ILC cells to survive hostile environments and infiltrate foreign tissues as single cells that have a tendency to remain dormant for extensive time periods.
The diffuse ILC growth patterns hinder early detection, especially in women with dense breasts.
Lobular Ireland are proud to be an active participant of the ELBCC patient advocacy group
The Elbcc – The European Lobular Breast Cancer Consortium was host to the https://ilcsymposium2022.com/ in Utrecht this Summer, you can now subscribe to the main Talks and Speaker Presentations using the link below.
https://www.youtube.com/channel/UCnwUJDYQl0hLTmkpfOGMgsg
The ELBCCC consortium https://elbcc.org/ was started in November 2018 with the intention to develop a platform to bring together discovery scientists, translational researchers and clinical experts, with the ultimate goal to improve the understanding, diagnosis, treatment and prognosis of women suffering from Invasive Lobular Breast cancer.
The ELBCC consortium aims at a better understanding of the genetic and biochemical cues that underpin Invasive Lobular Breast Cancer (ILC).
Their Patient information Leaflet, designed by ILC Clinicians, Patients and Researchers is now available to download in 11 different Languages. This is a great tool for newly diagnosed patients and we hope that Clinicians, Breast Nurses and Oncologists will make it available to their ILC patients and families. https://elbcc.org/Leaflet
Lobular Ireland 